Zoll Medical Corporation, a Chelmsford, MA-based Asahi Kasei Group Company that manufactures medical devices and related software solutions, acquired TherOx, Inc., an Irvine, Calif.-based company focused on improving treatment of acute myocardial infarction (AMI) and markets systems to deliver SuperSaturated Oxygen (SSO2) Therapy.
The amount of the deal was not disclosed.
This acquisition aims to expand the Zoll product portfolio.
Led by Kevin T. Larkin, President and CEO, TherOx is focused on commercializing SSO2 Therapy, a device that treats heart attack patients who suffer from acute myocardial infarction without interrupting door-to-balloon time. TherOx technology provides oxygenated fluids directly to the damaged area of the heart using a catheter placed after PCI and stenting.
Recently approved by the Federal Drug Administration (FDA), SSO2 Therapy has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients with left anterior descending ST-elevation myocardial infarction.
Led by Neil Johnston, President, Zoll Medical Corporation develops and markets medical devices and software solutions to advance emergency care while increasing clinical and operational efficiencies including products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation.